Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681105 · ClinicalTrials.gov registry record · Phase 1
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04681105 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT04681105, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Interventions
- DRUG Acetaminophen
- DRUG Ibuprofen
- DRUG Dexamethasone
- DRUG Diphenhydramine
- BIOLOGICAL Flotetuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2025-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681105
The ClinicalTrials.gov registry entry for NCT04681105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.
NCT04681105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04681105 about?
NCT04681105 is a clinical study titled "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies". This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment...
What is the current status of trial NCT04681105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2020-11-18. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT04681105?
The interventions under investigation include: Acetaminophen (DRUG), Ibuprofen (DRUG), Dexamethasone (DRUG), Diphenhydramine (DRUG), Flotetuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04681105?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.